

1625 JFW

Approved for use through 07/31/2006. OMB 0651-0032  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>FEE TRANSMITTAL</b> <b>for FY 2005</b> <i>Effective 10/01/2004. Patent fees are subject to annual revision.</i>		<b>Complete if Known</b>	
		Application Number	09/839,424
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27		Filing Date	April 20, 2001
		First Named Inventor	David L. Brown
		Examiner Name	Binta M. Robinson
<b>TOTAL AMOUNT OF PAYMENT</b> (\$)		Art Unit	1625
		Attorney Docket No.	3364/1/US
			<b>\$110.00</b>

<b>METHOD OF PAYMENT</b> (check all that apply)		<b>FEE CALCULATION</b> (continued)			
<input type="checkbox"/> Check <input type="checkbox"/> Credit card <input type="checkbox"/> Money Order <input type="checkbox"/> Other <input type="checkbox"/> None		<b>3. ADDITIONAL FEES</b>			
<input checked="" type="checkbox"/> Deposit Account:		<b>Large Entity</b>		<b>Small Entity</b>	
Deposit Account Number		Fee Code	Fee (\$)	Fee Code	Fee (\$)
Deposit Account Name		1051	130	2051	65
The Director is authorized to: (check all that apply)		Fee Description			
<input checked="" type="checkbox"/> Charge fee(s) indicated below <input checked="" type="checkbox"/> Credit any overpayments		Fee Paid			
<input checked="" type="checkbox"/> Charge any additional fee(s) or any underpayment of fee(s)		1052	50	2052	25
<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.					
<b>FEE CALCULATION</b>					
<b>1. BASIC FILING FEE</b>					
<b>Large Entity</b>					
Fee Code (\$)					
1001 790					
1002 350					
1003 550					
1004 790					
1005 160					
SUBTOTAL (1)		(\$)			
<b>2. EXTRA CLAIM FEES FOR UTILITY AND</b>					
Extra Claims		Fee from below			
Total Claims -20** = 0		Fee Paid			
Independent Claims -3** = 0					
Multiple Dependent					
<b>Large Entity</b>					
Fee Code (\$)					
1202 18					
1201 88					
1203 300					
1204 88					
1205 18					
SUBTOTAL (2)		(\$) \$0.00			
**or number previously paid, if greater; For Reissues, see above					
		SUBTOTAL (3) (\$)			
		<b>\$110.00</b>			

<b>SUBMITTED BY</b>		<b>Complete (if applicable)</b>	
Name (Print/Type)	Philip B. Polster, II	Registration No. (Attorney/Agent)	43,864
Signature		Telephone	314.274.9094
		Date	November 22, 2004

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on**

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**TERMINAL DISCLAIMER TO OBTAIN A PROVISIONAL DOUBLE  
PATENTING REJECTION OVER A PENDING SECOND APPLICATION**

Docket No.


3364/1/US

In re Application of: **David L. Brown et al.**

Application No. **09/839,424**

Filed: **April 20, 2001**

For: **2-FLUOROBENZENSULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION**



The owner, **Pharmacia Corporation** of **100.00** percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number **60/199533 and 60/253380**, filed on **04/25/2000 and 11/27/2000**. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

Check either box 1 or 2, if appropriate.

1. ☐ For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

2. ☒ The undersigned is an attorney of record.
3. Owner/applicant is ☐ Small entity ☒ Large entity

The terminal disclaimer fee under 37 CFR 1.20(d) is **\$110.00** and is to be paid as follows:

- ☐ A check in the amount of the fee is enclosed.
- ☒ The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number **19-1025**.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

PTO suggested wording for terminal disclaimer was

- ☒ unchanged. ☐ changed (if changed, an explanation should be supplied.)

  
Signature

Name and Address of Person Signing

**Philip B. Polster II, Reg. No. 43,864**  
**Pharmacia Corporation of Pfizer Inc.**  
**P.O. Box 1027**  
**Chesterfield, Missouri 63006**  
**314.274.9094**

Dated: **November 22, 2004**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

**November 22, 2004**

(Date)

  
Signature of Person Mailing Correspondence

**Linda K. Cooper**

Typed or Printed Name of Person Mailing Correspondence

11/29/2004 YPOLITE1 00000045 191025 09839424

01 FC:1814

110.00 DA